Company
Life Technologies
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
24
510(k), De Novo and PMA
Device trials
4
As lead sponsor, any status
Adverse event reports
39
Received Nov 1, 2025 to Nov 20, 2026
Recall records
31
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$0
1 Form D offering, 2009 to 2009
Equity
$0
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $0 raised, first sale Dec 15, 2009, 35 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Dec 15, 2009 | Equity Issued in a merger or acquisition; not counted as money raised | $0 | Open-ended | 35 | Rule 506 | Form D ↗Dec 24, 2009 |
Company details
From the company's latest Form D.
- Legal name
- Life Technologies Corp
- Headquarters
- Carlsbad, CA
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1073431 ↗
Executives, directors and promoters
As listed on the latest Form D.
24 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 24 since 2015.
K260431 · Decided Nov 5, 2026 · 282 days after receipt
Device type: Dura Substitute (GXQ) · Neurology & Neurosurgery
K260827 · Decided Oct 15, 2026 · 216 days after receipt
Device type: High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY) · Laboratory Medicine & Pathology
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
21 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry StudyActive, not recruiting
NCT02677974 · 510 participants · Start Nov 10, 2015 · Primary completion Apr 2027
Device: On-X Aortic Heart Valve replacement · For: Thrombotic and Bleeding Events
Sites: Tucson, Arizona; Hartford, Connecticut; Indianapolis, Indiana · 23 sites in all
- Randomized On-X Anticoagulation TrialPivotal-lookingCompleted
NCT00291525 · 977 participants · Start Jun 6, 2006 · Primary completion Aug 8, 2023
Device: On-X valve using reduced anticoagulation; On-X Valve with Standard warfarin Therapy · For: Heart Valve Disease
Sites: Tucson, Arizona; Loma Linda, California; Hartford, Connecticut · 49 sites in all
NCT01812174 · 20 participants · Start Nov 18, 2011 · Primary completion Dec 7, 2018
Device: 17mm aortic valve (On-X ); 23mm mitral valve (On-X) · For: Heart Valve Disease
Sites: Little Rock, Arkansas; Portland, Maine; Las Vegas, Nevada · 10 sites in all
1 more trials with a free account
Reports received
39
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
3
7.7% of reports
Injury reports
32
82% of reports
Death reports
4
10% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 3 | 0 | 0 |
| Jan 24 | 0 | 16 | 1 | 0 |
| Feb 24 | 0 | 3 | 1 | 0 |
| Mar 24 | 0 | 2 | 2 | 0 |
| Apr 24 | 0 | 1 | 0 | 0 |
| May 24 | 1 | 9 | 1 | 0 |
| Jun 24 | 0 | 2 | 1 | 0 |
| Jul 24 | 0 | 1 | 1 | 0 |
| Aug 24 | 0 | 5 | 0 | 0 |
| Sep 24 | 1 | 0 | 1 | 0 |
| Oct 24 | 0 | 8 | 6 | 0 |
| Nov 24 | 0 | 6 | 5 | 0 |
| Dec 24 | 0 | 3 | 0 | 0 |
| Jan 25 | 0 | 6 | 0 | 0 |
| Feb 25 | 0 | 2 | 0 | 0 |
| Mar 25 | 0 | 3 | 2 | 0 |
| Apr 25 | 0 | 3 | 0 | 0 |
| May 25 | 0 | 5 | 2 | 0 |
| Jun 25 | 0 | 3 | 1 | 0 |
| Jul 25 | 0 | 3 | 0 | 0 |
| Aug 25 | 0 | 5 | 0 | 0 |
| Sep 25 | 0 | 3 | 1 | 0 |
| Oct 25 | 0 | 3 | 0 | 0 |
| Nov 25 | 0 | 3 | 1 | 0 |
| Dec 25 | 0 | 1 | 0 | 0 |
| Jan 26 | 0 | 1 | 0 | 0 |
| Feb 26 | 1 | 3 | 2 | 0 |
| Mar 26 | 0 | 5 | 0 | 0 |
| Apr 26 | 0 | 1 | 0 | 0 |
| May 26 | 2 | 3 | 0 | 0 |
| Jun 26 | 0 | 5 | 0 | 0 |
| Jul 26 | 0 | 3 | 0 | 0 |
| Aug 26 | 0 | 3 | 1 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 4 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
1 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Ion Torrent Genexus Dx with software, Catalog: A40003539, which supports the Ion Torrent Genexus Dx Integrated SequencerOpen, Classified
Z-0211-2027 · Started Aug 14, 2026 · Posted by FDA Oct 22, 2026
Reason given: DNA or RNA sequencing system software has vulnerabilities.
Cause as FDA categorized it: Software design · Device type: High Throughput Dna Sequence Analyzer (PFF)
Z-2133-2026 · Started Feb 1, 2026 · Posted by FDA May 8, 2026
Reason given: Heart valves were released and distributed before all required testing was complete, so it cannot be confirmed that they meet all release specifications.
Cause as FDA categorized it: Under Investigation by firm · Device type: Heart-Valve, Mechanical (LWQ)
Z-1426-2024 · Started Feb 7, 2024 · Posted by FDA Mar 29, 2024
Reason given: Torrent Suite Dx Software versions 5.14 and earlier used in connection with Ion PGM DX Systems exploitation of the vulnerability by a threat actor may allow them to alter settings, configurations, software, or data on the instrument
Cause as FDA categorized it: Software design · Device type: High Throughput Dna Sequence Analyzer (PFF)
28 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.